SightfileU.S. market data from official filings

VIVOS THERAPEUTICS INC (VVOS)

Name: VIVOS THERAPEUTICS INC (VVOS) — Institutional ownership, SEC filings and insider activity
Creator: Sightfile
License: https://www.sec.gov/privacy#dissemination

Institutional ownership, SEC filings and insider activity

Sector: Healthcare & Pharma · SEC CIK 0001716166 · EDGAR filings · Updated 2026-07-15

VIVOS THERAPEUTICS INC (VVOS) has reported institutional ownership of 13.1%, with 24 institutional managers holding positions valued at $2.15M per the latest 13F reporting period. SEC filings include an active non-reliance notice on previously issued financial statements (8-K Item 4.02), notice of delisting or failure to satisfy a continued listing rule (8-K Item 3.01), substantial-doubt (going concern) disclosure per the filings.

Institutional ownership

13.1%

Institutional managers

Reported 13F value

$2.15M

Data flags

3 active

from SEC filings

Latest updates

2026-07-15 — SCHEDULE 13D filed
2026-07-15 — Insider transaction reported (Form 4)
2026-07-15 — Initial insider ownership filed (Form 3)
2026-07-07 — Current report (8-K) filed
2026-06-25 — Current report (8-K) filed
2026-06-16 — Current report (8-K) filed

Institutional ownership overview

According to SEC 13F filings tracked by Sightfile, VIVOS THERAPEUTICS INC has 24 institutional holders and institutional ownership of 13.1%.

Insider activity

Insiders reported 0 transactions (0 buys, 0 sells) across 2 reporting insiders, with a net reported value of $0.

Data flags from SEC filings

Active notice of delisting or failure to satisfy a continued listing rule (8-K Item 3.01), most recently filed 2026-06-08 (recurring since 2022-11-04) — source filing. The authoritative details are those stated in the filing itself.

Active substantial-doubt (going concern) disclosure per the filings, most recently filed 2026-05-20 (recurring since 2021-03-25) — source filing. The authoritative details are those stated in the filing itself.

Active non-reliance notice on previously issued financial statements (8-K Item 4.02), most recently filed 2022-11-22 (recurring since 2022-11-22) — source filing. The authoritative details are those stated in the filing itself.

Related companies

Outlook Therapeutics Inc (OTLK) · Q/C TECHNOLOGIES INC (QCLS) · SYNERGY CHC CORP (SNYR) · Reviva Pharmaceuticals Holdings Inc (RVPH) · RADIOPHARM THERANOSTICS LTD (RADX) · PURETECH HEALTH PLC (PRTCY)

See full history, cross-references and alerts on Sightfile

Sightfile provides information only — not investment advice, recommendations, or an assessment of any security. Data is derived from official public sources (SEC EDGAR and U.S. government agencies), may contain errors or delays, and should be verified against the source filing before relying on it.
Data sources: SEC EDGAR (filings, 13F, FTD), aggregated by Sightfile. Page updated 2026-07-15.